Prime Medicine receives a Buy upgrade from H.C. Wainwright after New Zealand clears its first in vivo prime editing trial for Wilson's disease. The FDA also granted RMAT designation to its CGD therapy PM359. Jacob Funds and ARK Investment have recently added to their positions in the gene-editing company.
The global CRISPR and prime editing market is forecast to grow at 24.1% CAGR through 2031, driven by therapeutic advances and regulatory progress. Scribe Therapeutics achieved a second milestone with Eli Lilly, while new RNA production and gene editing technologies accelerate research.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05189925 |
NADPH Oxidase Correction in mRNA-transfected Granulocyte-enriched Cells in Chronic Granulomatous Disease (CGD) |
RECRUITING | PHASE1 |
| NCT03910452 |
Haploidentical Transplant for People With Chronic Granulomatous Disease (CGD) Using Alemtuzumab, Busulfan and TBI With Post-Transplant Cyclophosphamide |
ACTIVE_NOT_RECRUITING | EARLY_PHASE1 |
| NCT03655223 |
Early Check: Expanded Screening in Newborns |
ACTIVE_NOT_RECRUITING | |
| NCT03645486 |
Lentiviral Gene Therapy for CGD |
RECRUITING | NA |
| NCT02116764 |
Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995 |
COMPLETED | |
| NCT02108028 |
Study of Voicing My CHOiCES as a Tool for Advanced Care Planning in Young Adults With Cancer |
COMPLETED | |
| NCT01652092 |
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies |
ACTIVE_NOT_RECRUITING | NA |
| NCT00368446 |
Genetic Disorders of Mucociliary Clearance in Nontuberculous Mycobacterial Lung Disease |
COMPLETED |
